Original Papers

The European Journal of Health Economics

, Volume 6, Issue 3, pp 244-252

First online:

Influenza treatment with neuraminidase inhibitors

Cost-effectiveness and cost-utility in healthy adults in the United Kingdom
  • Beate SanderAffiliated withInstitute for Medical Outcome Research GmbHDivision of Clinical Decision-Making & Health Care Research, University Health Network Email author 
  • , Marlene GyldmarkAffiliated withHealth Economics and Strategic Pricing, F. Hoffmann-La Roche Ltd Pharmaceuticals Division
  • , Frederick G. HaydenAffiliated withDivision of Infectious Diseases and International Health, School of Medicine, University of Virginia
  • , James MorrisAffiliated withRoche Products Ltd
  • , Elvira MuellerAffiliated withInstitute for Medical Outcome Research GmbH
  • , Rito BergemannAffiliated withInstitute for Medical Outcome Research GmbH

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


We assessed the cost-effectiveness and cost-utility of treating influenza with neuraminidase inhibitors (oseltamivir and zanamivir) from a health care payer’s and societal perspective in the United Kingdom. A simulation model was developed to predict morbidity and mortality due to influenza and its specified complications, comparing neuraminidase inhibitors with usual care in an otherwise healthy adult population. Robustness of the results was tested by one-way and multiway as well as probabilistic sensitivity analyses. Treatment with either neuraminidase inhibitor results in reduced morbidity and faster return to normal activities. However, oseltamivir dominates zanamivir in cost-utility analysis due to its lower costs. Comparing oseltamivir with usual care, the costs are £14.36 per day of normal activity gained and £5,600 per quality-adjusted life-year gained from the healthcare payer perspective. Oseltamivir dominates usual care from the societal perspective. Treatment with oseltamivir is a cost-effective strategy for otherwise healthy adults in the UK from both the healthcare payer and societal perspective.


Influenza Treatment Antivirals Cost-effectiveness Decision modeling